Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Notes Payables (2021 - 2023)

ImmunityBio (IBRX) has disclosed Notes Payables for 5 consecutive years, with $481.9 million as the latest value for Q2 2023.

  • On a quarterly basis, Notes Payables rose 60.59% to $481.9 million in Q2 2023 year-over-year; TTM through Jun 2023 was $481.9 million, a 60.59% increase, with the full-year FY2022 number at $431.9 million, up 44.33% from a year prior.
  • Notes Payables was $481.9 million for Q2 2023 at ImmunityBio, up from $29.9 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $481.9 million in Q2 2023 to a low of $29.9 million in Q1 2023.
  • A 3-year average of $307.1 million and a median of $299.8 million in 2022 define the central range for Notes Payables.
  • Biggest YoY gain for Notes Payables was 60.59% in 2023; the steepest drop was 90.02% in 2023.
  • ImmunityBio's Notes Payables stood at $299.2 million in 2021, then skyrocketed by 44.33% to $431.9 million in 2022, then rose by 11.58% to $481.9 million in 2023.
  • Per Business Quant, the three most recent readings for IBRX's Notes Payables are $481.9 million (Q2 2023), $29.9 million (Q1 2023), and $431.9 million (Q4 2022).